FDA Expands Use of Pembrolizumab to Two Additional Cancer Types

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.

Read More

Exploring Complement Biology to Improve Antibody-based Therapies for Non-Hodgkin Lymphoma

Among the many types of cancer acknowledged during the month of September is lymphoma, a cancer arising from a subset of white blood cells (lymphocytes) that compose an important part …

Read More